Redeye sees good prospects for continued growth as Acuvi appears to have a strong momentum with several large business projects coming on stream in 2023. The Q4 report held rather few surprises since preliminary numbers were previously announced. Our valuation is negatively impacted by a higher WACC and more cautious assumptions on sustainable margins.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Acuvi - Solid growth prospects

© Modular Finance, source Nordic Press Releases